Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
研究發現，諾和諾德公司的「奧塞米康」神奇減肥藥物可將癡呆風險降低48%
Novo Nordisk A/S. (NYSE:NVO) has found that its "miracle" weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues.
禮來（NYSE: NVO）發現其用於糖尿病的“神奇”減重藥物Ozempic與顯著降低癡呆和其他認知問題的風險相關。
What Happened: A study conducted at the University of Oxford revealed that patients who used Ozempic had a 48% lower risk of dementia compared to those who used an older drug, sitagliptin. The study also showed a lower risk of cognitive deficits in comparison to patients who had taken either sitagliptin or glipizide, another older medicine, reported Bloomberg on Friday.
發生了什麼：牛津大學的一項研究表明，使用Ozempic的患者患癡呆的風險降低了48％，而那些使用較舊藥物西格列汀的患者則較高。這項研究還顯示相比於那些服用西格列汀或另外一種老藥物格列吡嗪的患者，認知缺陷的風險也更低，Bloomberg週五報道。
Patients on Ozempic also had a 28% lower risk...
使用Ozempi...
登入免費觀看全文
登入/註冊